menu
    • menu
    [{"orgOrder":0,"company":"Otsuka Holdings","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tolvaptan Sodium Phosphate","moa":"V2 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Otsuka Holdings","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Otsuka Holdings \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Otsuka Holdings \/ Undisclosed"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tolvaptan Sodium Phosphate","moa":"V2 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Otsuka Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Otsuka Pharmaceutical \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals for Tolvaptan Sodium Phosphate

    Menu

    Tolvaptan Sodium Phosphate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Otsuka Holdings

                            Japan arrow
                            BOS Manchester
                            Not Confirmed

                            Otsuka Holdings

                            Japan arrow
                            BOS Manchester
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tolvaptan Sodium Phosphate

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Launch in Japan of SAMTASU® for IV Infusion, a V2 -Receptor Antagonist for the Treatment of Cardiac Edema

                            Details : SAMTASU is a prodrug of oral tolvaptan (generic name is tolvaptan sodium phosphate). A prodrug is a medication that is converted into an active drug in the human body following administration.

                            Product Name : Samtasu

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 30, 2022

                            Lead Product(s) : Tolvaptan Sodium Phosphate

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Otsuka Pharmaceutical

                            Japan arrow
                            BOS Manchester
                            Not Confirmed

                            Otsuka Pharmaceutical

                            Japan arrow
                            BOS Manchester
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tolvaptan Sodium Phosphate

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Otsuka Obtains Approval in Japan for SAMTASU® for I.V. Infusion, a V2 -Receptor Antagonist for the Treatment ...

                            Details : SAMTASU is a prodrug of oral tolvaptan (generic - tolvaptan sodium phosphate). A prodrug is a medication that is converted into an active drug in the human body. Tolvaptan, discovered by Otsuka, is a novel compound, antagonist of vasopressin V2-receptor.

                            Product Name : Samtasu

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 28, 2022

                            Lead Product(s) : Tolvaptan Sodium Phosphate

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth